980 related articles for article (PubMed ID: 23157203)
1. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
[No Abstract] [Full Text] [Related]
2. Key issues in inhibitor management in patients with haemophilia.
Gomez K; Klamroth R; Mahlangu J; Mancuso ME; Mingot ME; Ozelo MC
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s319-29. PubMed ID: 24333092
[No Abstract] [Full Text] [Related]
3. Management of factor VIII inhibitors: evolution and current status.
Bloom AL
Haemostasis; 1992; 22(5):268-75. PubMed ID: 1478538
[TBL] [Abstract][Full Text] [Related]
4. Switching haemophilia products and inhibitor risk: a United States' perspective.
Nance D; Rodgers GM
Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
[No Abstract] [Full Text] [Related]
5. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
[TBL] [Abstract][Full Text] [Related]
6. How I manage patients with inherited haemophilia A and B and factor inhibitors.
Ljung RCR
Br J Haematol; 2018 Feb; 180(4):501-510. PubMed ID: 29270992
[TBL] [Abstract][Full Text] [Related]
7. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
Hedner U
Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
[No Abstract] [Full Text] [Related]
8. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).
Hay CR; Baglin TP; Collins PW; Hill FG; Keeling DM
Br J Haematol; 2000 Oct; 111(1):78-90. PubMed ID: 11091185
[No Abstract] [Full Text] [Related]
9. Inhibitors in congenital coagulation disorders.
Key NS
Br J Haematol; 2004 Nov; 127(4):379-91. PubMed ID: 15521914
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors - cellular aspects and novel approaches for tolerance.
Scott DW
Haemophilia; 2014 May; 20 Suppl 4(0 4):80-6. PubMed ID: 24762281
[TBL] [Abstract][Full Text] [Related]
11. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors.
DiMichele DM; Kroner BL;
Thromb Haemost; 2002 Jan; 87(1):52-7. PubMed ID: 11848456
[TBL] [Abstract][Full Text] [Related]
12. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
Schimpf K; Schwarz P; Kunschak M
Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
[No Abstract] [Full Text] [Related]
13. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Scharrer I
Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
[TBL] [Abstract][Full Text] [Related]
14. Management of hemophilia patients with inhibitors.
Hedner U; Glazer S
Hematol Oncol Clin North Am; 1992 Oct; 6(5):1035-46. PubMed ID: 1400071
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for the treatment of high titre inhibitors in mild haemophilia A.
Dolničar MB; Rajić V; Kitanovski L; Debeljak M
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s345-7. PubMed ID: 23522890
[No Abstract] [Full Text] [Related]
16. Inhibitors in haemophilia: clinical aspects.
Dimichele D; Rivard G; Hay C; Antunes S
Haemophilia; 2004 Oct; 10 Suppl 4():140-5. PubMed ID: 15479387
[TBL] [Abstract][Full Text] [Related]
17. FEIBA versus NovoSeven in hemophilia patients with inhibitors.
Franchini M; Coppola A; Tagliaferri A; Lippi G
Semin Thromb Hemost; 2013 Oct; 39(7):772-8. PubMed ID: 24014071
[TBL] [Abstract][Full Text] [Related]
18. The management of hemophilia patients with inhibitors.
Nilsson IM
Transfus Med Rev; 1992 Oct; 6(4):285-93. PubMed ID: 1421831
[No Abstract] [Full Text] [Related]
19. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
Nilsson IM; Berntorp E
Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
[No Abstract] [Full Text] [Related]
20. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.
Astermark J
Haemophilia; 2006 Jul; 12 Suppl 3():52-60. PubMed ID: 16683997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]